TapewireFind a company

person · Reporting owner

PATOU GARY

Disclosed activity across 1 company

Tapewire entity
40437
SEC CIK
0001283535

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Xenon Pharmaceuticals Inc.XENE · Entity 2602DirectorJune 05, 2026June 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Xenon Pharmaceuticals Inc.

Report date June 05, 2026 · Filed June 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect24,896 Reported balance After 2026-06-05 transaction · row 1
1 source row

Row 1 · 2026-06-05 · Sale · Disposed 1,322 · Balance 24,896

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.

Common SharesSEC Table I · non-derivativeIndirectSee Note4,902 Reported balance Holding disclosure · report date 2026-06-05 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 4,902

F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.

F2: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 05, 2026 Filed Jun 9, 2026 01:19 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 1,322 $53.14 $70,251.08
Disclosure

SEC source: 0001193125-26-262672 · ownership.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,896

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the reporting person on August 17, 2025, solely to satisfy income tax obligations related to the vesting of RSUs granted on June 5, 2025.

Read SEC document
June 03, 2026 Filed Jun 4, 2026 01:04 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantRestricted Share Units · Derivative 1,593 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001193125-26-256126 · ownership.xml · derivative · entry 5

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,593

Underlying: Common Shares · 1,593 shares

Expires not disclosed

F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Read SEC document
June 03, 2026 Filed Jun 4, 2026 01:04 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantShare Option (Right to Buy) · Derivative 10,507 $0.00 Strike: $53.46 $0.00
Disclosure

SEC source: 0001193125-26-256126 · ownership.xml · derivative · entry 4

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,507

Underlying: Common Shares · 10,507 shares

Expires 2036-06-02

F3 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:04 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionRestricted Share Units · Derivative 2,645 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-256126 · ownership.xml · derivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,645 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · derivative.exercise_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · derivative.expiration_date: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
June 01, 2026 Filed Jun 4, 2026 01:04 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,645 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-256126 · ownership.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,218

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F1 · price: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 22:00 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantRestricted Share Units · Derivative 2,645 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-25-083329 · ownership.xml · derivative · entry 2

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,645

Underlying: Common Shares · 2,645 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

F2 · derivative.expiration_date: Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
June 05, 2025 Filed Jun 6, 2025 22:00 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantShare Option (Right to Buy) · Derivative 17,012 $0.00 Strike: $30.73 $0.00
Disclosure

SEC source: 0000950170-25-083329 · ownership.xml · derivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,012

Underlying: Common Shares · 17,012 shares

Expires 2035-06-04

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 3,086 $0.00 Strike: $13.48 $0.00
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · derivative · entry 9

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,086 shares

Expires 2025-05-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 3,500 $0.00 Strike: $7.38 $0.00
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · derivative · entry 8

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 3,500 shares

Expires 2026-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,040 $41.05 $83,742.00
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 6

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,573

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,046 $39.80 $41,630.80
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 5

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,613

F1 · price: Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 3,086 $13.48 $41,599.28
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 4

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,659

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,851 $41.11 $117,204.61
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,573

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 649 $39.80 $25,830.20
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 2

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,424

F1 · price: Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations.

Read SEC document
November 22, 2024 Filed Nov 23, 2024 00:48 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 3,500 $7.38 $25,830.00
Disclosure

SEC source: 0000950170-24-130378 · ownership.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 05, 2024 Filed Jun 5, 2024 21:43 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 15,542 $0.00 Strike: $38.16 $0.00
Disclosure

SEC source: 0000950170-24-069468 · ownership.xml · derivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,542

Underlying: Common Shares · 15,542 shares

Expires 2034-06-04

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 4, 2025 or (ii) the day before the date of the issuer's 2025 annual meeting of shareholders.

Read SEC document
December 14, 2023 Filed Dec 16, 2023 02:50 UTC Amendment Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 7,598 $41.05 $311,897.90
Disclosure

SEC source: 0000950170-23-070912 · ownership.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note

Disclosed balance after: 4,902

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F3 · ownership.nature: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 5,144 $0.00 Strike: $9.00 $0.00
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · derivative · entry 13

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 5,144 shares

Expires 2024-11-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 2,800 $0.00 Strike: $9.85 $0.00
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · derivative · entry 12

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,800 shares

Expires 2024-01-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 6,378 $0.00 Strike: $9.85 $0.00
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · derivative · entry 11

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,378 shares

Expires 2024-01-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 7,598 $41.05 $311,897.90
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 10

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Note

Disclosed balance after: 4,902

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.06, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F7 · ownership.nature: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 3,977 $39.84 $158,443.68
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 9

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,573

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,167 $39.68 $46,306.56
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 8

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,550

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 5,144 $9.00 $46,296.00
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 7

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,717

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,303 $39.10 $90,047.30
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 6

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,573

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.16, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 577 $39.68 $22,895.36
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 5

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,876

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,880 $9.85 $28,368.00
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 4

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,453

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F2 · price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 5,100 $38.94 $198,594.00
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,573

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $38.81 to $39.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 1,278 $39.68 $50,711.04
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 2

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,673

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F3 · price: Represents the closing price of the Company's common shares in U.S. dollars on December 12, 2023, which was converted to a Canadian dollar amount for purposes of net settlement calculations.

Read SEC document
December 13, 2023 Filed Dec 15, 2023 22:38 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 6,378 $9.85 $62,823.30
Disclosure

SEC source: 0000950170-23-070841 · ownership.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,951

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Pursuant to the terms of a Lock-Up Agreement executed by the Reporting Person in favor of the underwriters of the Company's follow-on public offering in November 2023, the Reporting Person is permitted to transfer up to 22,000 common shares beneficially owned prior to November 29, 2023 or received upon the exercise of an option to purchase common shares during the lock-up period.

F2 · price: The exercise price was converted to U.S. dollars from $10.78 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
June 02, 2023 Filed Jun 2, 2023 21:27 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 18,475 $0.00 Strike: $38.96 $0.00
Disclosure

SEC source: 0000950170-23-026190 · ownership.xml · derivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,475

Underlying: Common Shares · 18,475 shares

Expires 2033-06-01

F1 · derivative.exercise_date: Vesting 100% on the earlier of (i) June 1, 2024 or (ii) the day immediately preceding the day of the following year's annual meeting.

Read SEC document
November 25, 2022 Filed Nov 29, 2022 01:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 2,057 $0.00 Strike: $2.68 $0.00
Disclosure

SEC source: 0001209191-22-058916 · doc4.xml · derivative · entry 6

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,057 shares

Expires 2022-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F6 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable.

Read SEC document
November 25, 2022 Filed Nov 29, 2022 01:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 1,937 $34.79 $67,390.36
Disclosure

SEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 4

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,573

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $34.76 to $34.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
November 25, 2022 Filed Nov 29, 2022 01:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Tax withholdingCommon Shares 120 $34.37 $4,124.40
Disclosure

SEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,510

F3 · price: Represents the closing price of the Company's common shares on November 23, 2022 for purposes of net settlement calculations.

Read SEC document
November 25, 2022 Filed Nov 29, 2022 01:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,057 $2.68 $5,512.76
Disclosure

SEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 2

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,630

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
November 23, 2022 Filed Nov 29, 2022 01:41 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 SaleCommon Shares 2,057 $34.33 $70,609.61
Disclosure

SEC source: 0001209191-22-058916 · doc4.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,573

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $34.24 to $34.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
June 28, 2022 Filed Jun 29, 2022 21:40 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $30.11 $0.00
Disclosure

SEC source: 0001209191-22-039833 · doc4.xml · derivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2032-06-27

F1 · derivative.exercise_date: 100% of the common shares subject to the option will vest on the earlier of (i) the first anniversary of grant date and (ii) the day immediately preceding the day of the Issuer's next annual general meeting of shareholders.

Read SEC document
December 08, 2021 Filed Dec 10, 2021 21:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 2,057 $0.00 Strike: $3.67 $0.00
Disclosure

SEC source: 0001209191-21-069018 · doc4.xml · derivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,057 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F3 · derivative.exercise_date: 1/3 of the shares subject to the Option vested on January 1, 2013 (the "2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the 2012 Vesting Commencement Date over the following 2 years.

Read SEC document
December 08, 2021 Filed Dec 10, 2021 21:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,057 $3.67 $7,549.19
Disclosure

SEC source: 0001209191-21-069018 · doc4.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,630

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
June 03, 2021 Filed Jun 4, 2021 23:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $18.56 $0.00
Disclosure

SEC source: 0001209191-21-038431 · doc4.xml · derivative · entry 4

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Shares · 10,000 shares

Expires 2031-06-02

F3 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Read SEC document
March 17, 2021 Filed Jun 4, 2021 23:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 OtherCommon Shares 100 $19.49 $1,949.00
Disclosure

SEC source: 0001209191-21-038431 · doc4.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 100

F1 · ownership.nature: Shares acquired by the reporting person's son sharing the reporting person's household on the date of acquisition. Subsequent to the acquisition of the reported shares, the reporting person's son no longer shares a household with the reporting person and the reporting person no longer has a reportable beneficial interest in such shares. Subsequent ownership reports filed by the reporting person will not report these shares.

Read SEC document
October 28, 2020 Filed Oct 29, 2020 20:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 2,057 $0.00 Strike: $3.76 $0.00
Disclosure

SEC source: 0001209191-20-056222 · doc4.xml · derivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,057 shares

Expires 2020-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2013. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
October 28, 2020 Filed Oct 29, 2020 20:20 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,057 $3.76 $7,734.32
Disclosure

SEC source: 0001209191-20-056222 · doc4.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,573

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
June 01, 2020 Filed Jun 2, 2020 21:32 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $13.11 $0.00
Disclosure

SEC source: 0001209191-20-033653 · doc4.xml · derivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Shares · 10,000 shares

Expires 2030-05-31

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Read SEC document
December 04, 2019 Filed Dec 6, 2019 22:12 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 2,057 $0.00 Strike: $3.56 $0.00
Disclosure

SEC source: 0001209191-19-059515 · doc4.xml · derivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,057 shares

Expires 2019-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

Read SEC document
December 04, 2019 Filed Dec 6, 2019 22:12 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,057 $3.56 $7,322.92
Disclosure

SEC source: 0001209191-19-059515 · doc4.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 22:51 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 GrantStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $9.44 $0.00
Disclosure

SEC source: 0001209191-19-050146 · doc4.xml · derivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Shares · 15,000 shares

Expires 2029-09-15

F1 · derivative.exercise_date: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.

Read SEC document
December 14, 2018 Filed Dec 18, 2018 21:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 2,057 $0.00 Strike: $3.07 $0.00
Disclosure

SEC source: 0001171843-18-008471 · ownership.xml · derivative · entry 3

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 2,057 shares

Expires 2018-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.

F3 · derivative.exercise_date: The shares subject to the option fully vested on December 31, 2011.

Read SEC document
December 14, 2018 Filed Dec 18, 2018 21:06 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionCommon Shares 2,057 $3.07 $6,314.99
Disclosure

SEC source: 0001171843-18-008471 · ownership.xml · nonDerivative · entry 1

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

Read SEC document
June 14, 2018 Filed Jun 15, 2018 23:32 UTC Xenon Pharmaceuticals Inc. XENE · Entity 2602 Exercise / conversionStock Option (Right to Buy) · Derivative 8,230 $0.00 Strike: $3.70 $0.00
Disclosure

SEC source: 0001171843-18-004695 · formfour.xml · derivative · entry 4

PATOU GARY · CIK 0001283535 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,230 shares

Expires 2018-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.

F4 · derivative.exercise_date: The shares subject to the option fully vested on May 31, 2011.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.